Effect of Tripterygium Wilfordii in Patients with Diabetic Nephropathy: a Prospective Randomized Control Clinical Trial

GE Yong-chun,XIE Hong-lang,LI Shi-jun,HOU Jin-hua,ZHANG Hai-tao,SHI Ming-jun,LIU Zhi-hong
DOI: https://doi.org/10.3969/j.issn.1006-298x.2010.06.001
2010-01-01
Abstract:Objective:To evaluate the clinical effects of Tripterygium wilfordii (TW) treatment for patients with type 2 diabetic nephropathy (T2DN) who have heavy proteinuria. Methodology:Sixty-five patients with DN whose proteinuria more than 2.5g/24h,serum creatinine (SCr) less than 265.2 μmol/L,younger than 70 years old and no cardiovascular events in the past six months,were enrolled in this study. They were randomized divided into two groups:TW treatment group (n=34,treated with TW 120 mg/d for 3 months,and then tapered to maintenance dose of 60 mg/d for 3 months)and ARB control group (n=31,treated with valsartan 160 mg/d for 6 months). At the end-point,the decrease of proteinuria,the increase of SCr and the side effects of TW were evaluated,and the clinical and pathological factors which influence the therapeutic effect were also investigated. Results:At the treatment end-point,the level of proteinuria was dramaticly decreased in TW group compared with that of baseline [(4.99±2.25) vs (2.99±1.81)g/24h,P0.01],and the percentage of the decrease at month 1,3,and 6 was 32.9%,38.8%,and 34.3% respectively. But the level of proteinuria in ARB group was not significantly decreased,the percentage of the decrease were 1.05%,10.1%,and-11.7% respectively. The increase ratio of SCr in ARB group was significantly higher than that in TW group(36.9% vs 20.3%,P0.05)and the decrease ratio of eGFR in ARB group was also significantly higher than that in TW group(24.6% vs 13.7%,P0.05). No statistics difference of side effects was observed between the two groups. Conclusion:Tripterygium wilfordii was a novel effective and safe drug for treatment of DN patients with heavy proteinuria.
What problem does this paper attempt to address?